Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease

被引:36
作者
Kosaka, T [1 ]
Sawada, K [1 ]
Ohnishi, K [1 ]
Egashira, A [1 ]
Yamamura, M [1 ]
Tanida, N [1 ]
Satomi, M [1 ]
Shimoyama, T [1 ]
机构
[1] Hyogo Coll Med, Dept Internal Med 4, Nishinomiya, Hyogo 6638501, Japan
关键词
lymphocytapheresis; human leukocyte antigen (HLA)-DR; cytokine; CD4(+)CD45(+);
D O I
10.2169/internalmedicine.38.102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Eighteen patients with active Crohn's disease were treated with one leukocytapheresis session per meek for a five-week intensive therapy, decreasing to one leukocytapheresis session per month for five sessions of initial maintenance therapy. Nutritional indices, inflammatory reactions, flow cytometry profiles, and cytokine production were also assessed before and after the intensive and initial maintenance therapy. Nine of the patients (50%) attained remission at the end of the intensive therapy. The nine non-remission patients had exhibited longer periods of suffering and more severely affected sites prior to the therapy. In 14 of 18 patients (77.8%), the nutritional indices, Internal Organization of Inflammatory Bowel Disease (IOIBD) score and Crohn's Disease Activity Index (CDAI) improved from the pretherapy levels, but only the remission group (50%) showed improvement in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). The remission group showed. significantly higher pretherapy CD4(+)CD45(+) cell ratios and interleukin-2 (IL-2) production than the non-remission group, and significantly lower activated cells.
引用
收藏
页码:102 / 111
页数:10
相关论文
共 34 条
[1]  
AMANO K, 1994, JPN J APHERESIS, V13, P61
[2]   PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMSTAT MESILATE .1. INHIBITION OF PROTEASE ACTIVITY IN INVITRO AND INVIVO EXPERIMENTS [J].
AOYAMA, T ;
INO, Y ;
OZEKI, M ;
ODA, M ;
SATO, T ;
KOSHIYAMA, Y ;
SUZUKI, S ;
FUJITA, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 35 (03) :203-227
[3]   LYMPHOKINE GENE-EXPRESSION RELATED TO CD4 T-CELL SUBSET (CD45R/CDW29) PHENOTYPE CONVERSION [J].
BETTENS, F ;
WALKER, C ;
GAUCHAT, JF ;
GAUCHAT, D ;
WYSS, T ;
PICHLER, WJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (09) :1569-1574
[4]   THE CURRENT STATUS OF LYMPHOCYTE-T APHERESIS (TLA) TREATMENT OF CROHNS-DISEASE [J].
BICKS, RO ;
GROSHART, KD .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1989, 11 (02) :136-138
[5]  
BROOKE BN, 1976, LANCET, V1, P1041
[6]   2 TYPES OF MOUSE HELPER T-CELL CLONE .3. FURTHER DIFFERENCES IN LYMPHOKINE SYNTHESIS BETWEEN TH1 AND TH2 CLONES REVEALED BY RNA HYBRIDIZATION, FUNCTIONALLY MONOSPECIFIC BIOASSAYS, AND MONOCLONAL-ANTIBODIES [J].
CHERWINSKI, HM ;
SCHUMACHER, JH ;
BROWN, KD ;
MOSMANN, TR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (05) :1229-1244
[7]   CLINICAL PHARMACOKINETICS OF SULFASALAZINE [J].
DAS, KM ;
DUBIN, R .
CLINICAL PHARMACOKINETICS, 1976, 1 (06) :406-425
[8]   IOIBD .1. OBSERVER VARIATION IN CALCULATING INDEXES OF SEVERITY AND ACTIVITY IN CROHNS-DISEASE [J].
DEDOMBAL, FT ;
SOFTLEY, A .
GUT, 1987, 28 (04) :474-481
[9]   TREATMENT OF INFLAMMATORY BOWEL-DISEASE WITH ANTI-CD4 MONOCLONAL-ANTIBODY [J].
EMMRICH, J ;
SEYFARTH, M ;
FLEIG, WE ;
EMMRICH, F .
LANCET, 1991, 338 (8766) :570-571
[10]   HYPERALIMENTATION AS PRIMARY THERAPY FOR INFLAMMATORY BOWEL DISEASE [J].
FISCHER, JE ;
FOSTER, GS ;
ABEL, RM ;
ABBOTT, WM ;
RYAN, JA .
AMERICAN JOURNAL OF SURGERY, 1973, 125 (02) :165-175